Abstract
Tuberculosis is the second leading cause of death from infectious diseases. Although antitubercular drugs have been traditionally administered orally, there is a growing interest in delivering drugs via the pulmonary route using nebulisers or dry powder inhalers. Drugs in dry powder inhalers (DPI) are stable and DPI are user-friendly compared to nebulisation which is time consuming, inconvenient and inefficient and requires special equipment. For tuberculosis treatment, drugs should target alveolar macrophages that harbour microorganisms and/or maintain high drug concentration at the infection site in the lung. Drug particles include micro-particles or nanoparticles. Powders can be engineered by micronisation, crystallisation, spray drying, freeze drying and particle coating approaches. The formulation may contain single or combination drugs. This paper will provide an update on current status of TB, its pathogenesis, current treatment strategies, shortcomings of current oral or parenteral delivery strategies, pulmonary delivery devices, advantages of pulmonary delivery of powder formulations, formulation approaches and pharmacokinetic studies of pulmonary delivery of powders for inhalation.
Keywords: Dry powder inhaler, microparticles, powder formulation, pulmonary delivery, spray drying, tuberculosis.
Current Drug Delivery
Title:Inhaled Dry Powder Formulations for Treating Tuberculosis
Volume: 12 Issue: 1
Author(s): Shyamal Das, Ian Tucker and Peter Stewart
Affiliation:
Keywords: Dry powder inhaler, microparticles, powder formulation, pulmonary delivery, spray drying, tuberculosis.
Abstract: Tuberculosis is the second leading cause of death from infectious diseases. Although antitubercular drugs have been traditionally administered orally, there is a growing interest in delivering drugs via the pulmonary route using nebulisers or dry powder inhalers. Drugs in dry powder inhalers (DPI) are stable and DPI are user-friendly compared to nebulisation which is time consuming, inconvenient and inefficient and requires special equipment. For tuberculosis treatment, drugs should target alveolar macrophages that harbour microorganisms and/or maintain high drug concentration at the infection site in the lung. Drug particles include micro-particles or nanoparticles. Powders can be engineered by micronisation, crystallisation, spray drying, freeze drying and particle coating approaches. The formulation may contain single or combination drugs. This paper will provide an update on current status of TB, its pathogenesis, current treatment strategies, shortcomings of current oral or parenteral delivery strategies, pulmonary delivery devices, advantages of pulmonary delivery of powder formulations, formulation approaches and pharmacokinetic studies of pulmonary delivery of powders for inhalation.
Export Options
About this article
Cite this article as:
Das Shyamal, Tucker Ian and Stewart Peter, Inhaled Dry Powder Formulations for Treating Tuberculosis, Current Drug Delivery 2015; 12 (1) . https://dx.doi.org/10.2174/1567201811666140716123050
DOI https://dx.doi.org/10.2174/1567201811666140716123050 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the Methyl Erythritol Phosphate (MEP) Pathway for Novel Antimalarial, Antibacterial and Herbicidal Drug Discovery: Inhibition of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase (DXR) Enzyme
Current Pharmaceutical Design Microwave Induced One Pot Ugi Multicomponent Reaction of Fluoroquino Lone Scaffolds: Their Biological Evaluation
Current Green Chemistry Old Drugs and New Targets as an Outlook for the Treatment of Tuberculosis
Current Medicinal Chemistry Drug Metabolizing Enzymes and Transporters mRNA in Peripheral Blood Mononuclear Cells of Healthy Subjects: Biological Variations and Importance of Preanalytical Steps
Current Drug Metabolism A Comparative Study to Explore the Effect of Different Compounds in Immune Proteins of Human Beings Against Tuberculosis: An In-silico Approach
Current Bioinformatics Malaria and Leishmaniasis: Current Status of Chemotherapy, New Leads and Targets for Drug Discovery
Anti-Infective Agents in Medicinal Chemistry Rediscovering the Antibiotics of the Hive
Recent Patents on Anti-Infective Drug Discovery The Evolution of Extensively Drug Resistant Tuberculosis (XDR-TB): History, Status and Issues for Global Control
Infectious Disorders - Drug Targets The Cell-Wall Core of Mycobacterium tuberculosis in the Context of Drug Discovery.
Current Topics in Medicinal Chemistry Benefits of Structural Genomics for Drug Discovery Research
Infectious Disorders - Drug Targets Pulmonary Disease in Beta-Thalassemia
Current Respiratory Medicine Reviews On the Paradigm Shift Towards Multitarget Selective Drug Design
Current Computer-Aided Drug Design Biosurfactants as a Novel Additive in Pharmaceutical Formulations: Current Trends and Future Implications
Current Drug Metabolism Therapeutic Potentials of Scavenger Receptor CD36 Mediated Innate Immune Responses Against Infectious and Non-Infectious Diseases
Current Drug Discovery Technologies Quantification of Rifaximin in Tablets by an Environmentally Friendly Visible Spectrophotometric Method
Current Pharmaceutical Analysis Reviving an Old HIV-1 Gene: The HIV-1 Antisense Protein
Current HIV Research Triazole-linked Chalcone and Flavone Hybrid Compounds Based on AZT Exhibiting In Vitro Anti-Cancer Activity
Letters in Drug Design & Discovery Synthetic Genomics and Synthetic Biology Applications Between Hopes and Concerns
Current Genomics Identification of Cancerlectins By Using Cascade Linear Discriminant Analysis and Optimal g-gap Tripeptide Composition
Current Bioinformatics Ischemic Colitis: Current Diagnosis and Treatment
Current Drug Targets